Betaxolol 0.5% versus Brimonidine 0.2% prophylactic effect on IOP elevation after Nd: YAG Laser posterior capsulotomy

Comparison of prophylactic effect of Betaxolol 0.5% with Brimonidine 0.2% on IOP elevation after Nd: YAG Laser posterior capsulotomy in patients with posterior capsule opacity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200901048577N1

Enrollment

Registered

2020-09-23

Start date

2019-08-23

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posterior capsule opacification. Age-related cataract

Interventions

Intervention 1: Intervention group 1: one drop of betaxolol 0.5% (Sina Darou) is instilled into the lower fornix of the eye, 1 hour before Nd:YAG laser posterior capsulotomy. Intervention 2: Intervent

Eligibility

Sex/Gender

All

Age

21 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with PCO after cataract surgery above 21 years old

Exclusion criteria

Exclusion criteria: Patients with glaucoma (or history of glaucoma surgery) cup to disc ratio greater than 0.5 intraocular pressure greater than 21 mmHg active uveitis active ocular infection pregnancy unstable cardiovascular condition severe asthma and lung disease Taking systemic or topical alpha 2 agonists, prostaglandin analogues, parasymapathomimetics, beta-blockers, carbonic anhydrase inhibitors

Design outcomes

Primary

Measure	Time frame
Intraocular pressure. Timepoint: 1 hour before laser application and 4 hours after that. Method of measurement: Goldmann Applanation tonometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Saber

Semnan University of Medical Sciences

Lnaz_saber@yahoo.com+98 23 3344 1022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026